5-Amino-1MQ is not a peptide but a membrane-permeable small molecule with a very specific job: inhibiting nicotinamide N-methyltransferase, or NNMT. This primer explains what the enzyme does, why blocking it became a research strategy, what the preclinical record shows, and how a laboratory should handle a small-molecule inhibitor alongside the peptides it is usually studied with.
The Enzyme: NNMT
Nicotinamide N-methyltransferase takes a methyl group from S-adenosylmethionine (SAM), the cell’s universal methyl donor, and attaches it to nicotinamide, producing 1-methylnicotinamide (1-MNA), which is excreted. In doing so it consumes two things the cell would otherwise use: nicotinamide, which the salvage pathway would recycle into NAD+, and a methyl group, which would otherwise be available for methylating DNA, histones, and proteins. The enzyme is expressed most heavily in the liver, where it has a housekeeping role in clearing excess nicotinamide, and in endocrine tissue, where its function was long unclear.
Why NNMT Matters
The research interest began with the observation that NNMT expression in white endocrine tissue is markedly elevated in metabolic-model and insulin-resistant rodents and humans, and that expression levels track with body-mass index and insulin resistance. A 2014 study showed that knocking down NNMT in mice protected against diet-induced metabolic disease and increased energy expenditure in fat cells, which established the enzyme as a candidate target. The proposed logic is that high NNMT activity in fat drains the NAD+ precursor pool and the methyl-donor pool at once, dampening NAD+-dependent sirtuin signaling and altering the cell’s energy balance; inhibiting it, in principle, preserves both.
NNMT also appears in cancer biology, where many tumors overexpress it, and the resulting “methyl sink” alters the epigenetic state of the cell. That literature is separate from the metabolic one but relies on the same inhibitors.
The Compound
5-Amino-1MQ (5-amino-1-methylquinolinium) was developed in the 2010s at the University of Texas Southwestern as a selective, cell-permeable NNMT inhibitor. It is a small quinolinium salt (about 159 Da for the cation) that mimics the nicotinamide substrate and binds the enzyme’s active site, with reported selectivity over related methyltransferases. Its small size and positive charge let it enter cells readily, which the first-generation inhibitors could not do, and it is the compound most of the recent preclinical literature uses.
What Preclinical Work Examines
Published studies focus on adipocyte metabolism. In cultured fat cells, NNMT inhibition increases intracellular NAD+ and SAM, reduces lipid accumulation, and shrinks lipid droplets. In diet-induced metabolic-model mice, the compound reduced metabolic and fat mass without changing feeding-pathway, with the effect attributed to increased energy expenditure in endocrine tissue; it also lowered plasma cholesterol in those models. More recent work has examined muscle: NNMT rises in aged and injured muscle, and inhibition has been reported to improve muscle stem-cell function and regeneration in old mice. The compound gives laboratories a clean pharmacological handle on a single enzyme node inside a complex metabolic network, which is rarer than it sounds.
Open Questions
- Which effect drives the outcome. NNMT inhibition raises NAD+ and SAM simultaneously; whether the metabolic effects come through NAD+/sirtuin signaling, through methylation changes, or through 1-MNA itself (which has its own signaling roles) is not settled.
- Tissue selectivity. The liver’s housekeeping NNMT activity is also inhibited; the consequences of chronic hepatic inhibition are less studied than the endocrine effects.
- Translation. The rodent weight-loss effect is robust; whether it reflects human endocrine biology is untested.
The NAD+ Connection
5-Amino-1MQ research naturally complements direct NAD+ studies and mitochondrial work with MOTS-C, three angles on the same energy-metabolism axis: supplying the coenzyme directly, preventing its precursor from being drained, and probing the mitochondrial signaling that depends on it. See Why NAD+ Declines With Age for the biology of the decline and Mitochondrial Research Compounds Compared for the mitochondrial shelf. An informative design pairs an NNMT inhibitor with an NAD+ measurement, since the inhibitor’s predicted effect is a measurable rise in cellular NAD+ that confirms target engagement.
Handling a Small Molecule Among Peptides
Because 5-Amino-1MQ is not a peptide, the usual peptide handling rules partly do not apply. It is a stable, water-soluble salt with no residues to oxidize or deamidate; its main sensitivities are light (quinolinium compounds can photodegrade) and, as with any charged small molecule, adsorption to some plastics at very low concentration. Store the solid cold, dry, and dark; reconstitute in water or bacteriostatic water; and protect solutions from light. A Certificate of Analysis for a small molecule should confirm identity by mass spectrometry (the cation at about 159 Da) and purity by HPLC, as for a peptide. Note that it is typically supplied as a salt (often the iodide or chloride), so the mass of the solid includes the counter-ion; use the molecular weight of the salt for concentration calculations.
All three compounds are in our Cellular & Mitochondrial Research and General Research collections, each batch third-party tested with a Certificate of Analysis.
All products discussed are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.



